We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




High T-Cell Counts Make Better Match for Stem-Cell Transplants

By LabMedica International staff writers
Posted on 30 Jun 2015
Print article
Image: Scanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor (Photo courtesy of The National Institute of Allergy and Infectious Diseases).
Image: Scanning electron micrograph of a human T lymphocyte (also called a T cell) from the immune system of a healthy donor (Photo courtesy of The National Institute of Allergy and Infectious Diseases).
A simple blood test that measures the T lymphocyte count in donors for stem cell transplants may help identify the best match for patients in need of an allogeneic stem cell transplant.

Older individuals with blood cancers are often treated with reduced-intensity allogeneic stem cell transplants, in which the chemotherapy or radiation dose is reduced, resulting in fewer side effects for patients.

Scientists at the University of Pennsylvania Perelman School of Medicine (Philadelphia, PA, USA) retrospectively evaluated associations between T cell doses present in the transplant graft and outcomes in 200 patients from the Abramson Cancer Center (ACC) at the University with blood cancers such as acute myeloid leukemia, myelodysplastic syndrome, non-Hodgkin lymphoma, and others. Knowing that CD8 cells can kill cancer cells, while CD4 cells help suppress or regulate immune responses, the investigators examined these two types of T-cells closely and found that the numbers of CD8 cells in the stem-cell graft had a dramatic impact on survival. They also found that high CD8 cell counts were much more common among young donors.

To characterize the CD34 and T cell doses, 10 × 106 cells were removed from the peripheral blood stem-cell (PBSC) product prior to the infusion and cell content was analyzed by flow cytometry. The doses of CD3, CD4 and CD8 cells were determined by flow cytometry conducted on FACSCanto flow cytometer (BD Biosciences; San Jose, CA, USA) using antibodies against CD45, CD3, CD4 and CD8. Higher CD8 cell doses were associated with a lower risk for relapse and improved relapse-free survival and overall survival without a significant increase in graft-versus-host disease or nonrelapse mortality. A cutoff level of 0.72 × 108 CD8 cells/kg optimally segregated patients receiving CD8hi and CD8lo grafts with differing overall survival. Donor age inversely correlated with graft CD8 dose and consequently, older donors were unlikely to provide a CD8hi graft, whereas approximately half of younger donors provided CD8hi grafts.

The four-year overall survival rates were 59% for younger, unrelated donor grafts with high CD8 counts, 18% for younger, unrelated donor grafts with low CD8 counts, and 33% for older, human leukocyte antigen (HLA)-matched sibling donor grafts . This suggests it would be better to use a younger unrelated donor graft with high CD8 cells instead of an older sibling donor. Additionally, the CD8 cell content of the graft could be predicted by measuring the proportion of CD8 cells in a blood test from potential stem cell donors, providing a simple way to screen for the best donor even before the stem cell graft was collected.

Ran Reshef, MD, an assistant professor at ACC and lead author of the study, said, “There may be suitable donors out there who are overlooked because they are considered a poorer match by today’s donor selection algorithms. Refining the screening method could greatly increase the chances of finding the most appropriate donor, one that will induce the most potent graft-vs-tumor response. This is a method deserving additional investigation, which could refine the standardized matching system used by registries, such as Be the Match and others, and ultimately optimize the donor pool for older patients undergoing these transplants.” The study was published on June 8, 2015, in the Journal of Clinical Oncology.

Related Links:

University of Pennsylvania Perelman School of Medicine
BD Biosciences 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.